Hematology | Topics

 
FDA Approves Ruxolitinib for the Treatment of Previously Treated Chronic Graft-Versus-Host Disease
September 22, 2021

Patients with chronic graft-versus-host disease who have received prior therapy can now receive treatment with ruxolitinib following its approval by the FDA.

Outpatient Haploidentical Stem Cell Transplantation
September 14, 2021

The latest episode of the ASTCT Talks episode features a discussion from Andrés Gómez De León, MD, and Perla Colunga, MD, on outpatient haploidentical stem cell transplantation.

FDA Approves Zanubrutinib for the Treatment Waldenströms Macroglobulinemia
September 01, 2021

Zanubrutinib has been approved by the FDA for the treatment of patients with Waldenströms macroglobulinemia based on the results of the phase 3 ASPEN trial.